Bruton’s Tyrosine Kinase Inhibitors for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis
Journal of Cutaneous Medicine and Surgery · 17.04.2026
DOI: 10.1177/12034754261418239 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cutaneous Medicine and Surgery, online erschienen am 17.04.2026. Verfasst von Martin Cevallos-Cueva und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Universidad Central del Ecuador, Quito, Ecuador. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Although second-generation H1 antihistamines remain the first-line treatment for chronic spontaneous urticaria (CSU), a significant proportion of patients experience inadequate symptom control, highlighting the ongoing need for more effective and targeted treatment strategies. We conducted a systematic review and meta-analysis of 5 randomized controlled trials (RCTs) comparing Bruton’s tyrosine kinase (BTK) inhibitors with placebo at 4, 8, and 12 weeks in patients with CSU. We searched PubMed, Embase, and CENTRAL (Cochrane Central Register of Controlled Trials) from inception to April 2025. The primary outcomes assessed included the Weekly Urticaria Activity Score (UAS7), complete absence of pruritus and urticaria (UAS7 = 0), well-controlled CSU (UAS7 ≤ 6), and safety outcomes. Across 5 included RCTs, 1071 (71.93%) patients received BTK inhibitors. BTK inhibitors significantly increased the likelihood of achieving UAS7 = 0 at week 4 [risk ratio (RR) 5.64; 95% confidence interval (CI) 1.04-30.70; P = .05], week 8 (RR 3.78; 95% CI 2.48-5.76; P < .00001), and week 12 (RR 2.68; 95% CI 1.28-5.62; P = .02). Consistent findings were observed for UAS7 ≤ 6 at week 4 (RR 4.30; 95% CI 3.06-6.03; P < .00001), week 8 (RR 2.60; 95% CI 2.02-3.33; P < .00001), and week 12 (RR 2.05; 95% CI 1.68-2.50; P < .00001). Neither the incidence of adverse events (AEs; RR 1.06; 95% CI 0.84-1.33; P = .47), nor serious AEs (RR 1.17; 95% CI 0.34-4.02; P = .71) was significantly different between groups. BTK inhibitors offer a valuable, safe, and effective treatment option for CSU, particularly in cases that are refractory to second-generation H1 antihistamines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Universidad Central del Ecuador, Quito, Ecuador.
- Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
- Dermatology Department, Ohio Health, Columbus, OH, USA.
- John Sealy School of Medicine, The University of Texas Medical Branch, Galveston, TX, USA.
- Medgate AG, Allschwil, Switzerland.
- University Clinic for Psychiatry and Psychotherapy, Paracelsus Medical University, Nuremberg, Germany.
ORCID-Profile: Martin Cevallos-Cueva, Laura Ghanem, Guilherme Kuceki, Chinenye Onejeme, Cristina Sicorschi Gutu, Daniela L Mendoza-Millán, Esteban Fernandez-Faith
Zitieren
APA
Cevallos-Cueva, M., Ghanem, L., Kuceki, G., Onejeme, C., Sicorschi Gutu, C., Mendoza-Millán, D. L., & Fernandez-Faith, E. (2026). Bruton’s Tyrosine Kinase Inhibitors for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis. Journal of Cutaneous Medicine and Surgery. https://doi.org/10.1177/12034754261418239
Vancouver
Cevallos-Cueva M, Ghanem L, Kuceki G, Onejeme C, Sicorschi Gutu C, Mendoza-Millán DL, et al. Bruton’s Tyrosine Kinase Inhibitors for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis. Journal of Cutaneous Medicine and Surgery. 2026. doi:10.1177/12034754261418239
BibTeX
@article{CevallosCueva2026,
author = {Cevallos-Cueva, Martin and Ghanem, Laura and Kuceki, Guilherme and Onejeme, Chinenye and Sicorschi Gutu, Cristina and Mendoza-Millán, Daniela L and Fernandez-Faith, Esteban},
title = {Bruton’s Tyrosine Kinase Inhibitors for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis},
journal = {Journal of Cutaneous Medicine and Surgery},
year = {2026},
doi = {10.1177/12034754261418239}
}
EUVIMED